Telmisartan+Amlodipine Fixed Dose Combination in Hypertension

Model scores of the 29,894 trials active now.

Model score 6% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (493 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: to severemoderate tokidneywith moderate24
  Phrases that lowered it: evaluate theto evaluateblood pressuremmhgdiastolic blood
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Sponsor's past termination rate: 4.4% (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 9.4% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: not given (lowers risk) · Design
• Design: single group (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 76.9% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 190 (lowers risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 12052 (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 47708 (lowers risk) · Drug's FDA history
• Disease area, neurology: No (lowers risk) · Disease area
• Sponsor's past trials: 90 (lowers risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Maximum age: 80 (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Add-on to Micamlo BP Trial NCT01975246 · started 2013 · scored riskier than 5% of active trials completed
• An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy NCT01103960 · started 2010 · scored riskier than 9% of active trials completed
• Open Label Study Telmisartan and Amlodipine in Hypertension NCT00614380 · started 2008 · scored riskier than 8% of active trials completed
• Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine NCT01911780 · started 2013 · scored riskier than 5% of active trials completed
• Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension NCT00860262 · started 2009 · scored riskier than 15% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.